Literature DB >> 6174161

New and rapid functional assay for C1 inhibitor in human plasma.

M Schapira, L D Silver, C F Scott, R W Colman.   

Abstract

C1 inhibitor (C1-INH) and alpha 2-macroglobulin (alpha 2M) account for over 90% of the inactivation of purified plasma kallikrein by normal human plasma. The rate of kallikrein inactivation is also dependent on the presence of high molecular weight kininogen (HMWK), which forms a reversible complex with kallikrein protecting the active site of the enzyme against inhibitors. By selectively inactivating alpha 2M with methylamine, and eliminating the protective effect of HMWK by dilution, the inactivation of kallikrein by plasma became almost exclusively dependent on C1-INH. Functional C1 inhibitor was assessed by measuring the pseudo-first-order rate constant for the inactivation of kallikrein by diluted methylamine-treated plasma in 29 individuals, including 11 controls, 11 oral contraceptive users, 5 patients with classical hereditary angioedema (HAE), and 2 patients with variant HAE. Over a wide range of concentrations, an excellent correlation (r = 0.90) was observed between functional and antigenic C1-INH among controls, oral contraceptive users, and patients with classical HAE. This new functional assay for C1-INH can be performed in less than 3 hr with commercially available reagents. Therefore, this assay will be helpful for the diagnosis and management of conditions associated with the deficiency of C1-INH, such as HAE.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6174161

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

2.  High molecular weight kininogen is an inhibitor of platelet calpain.

Authors:  A H Schmaier; H Bradford; L D Silver; A Farber; C F Scott; D Schutsky; R W Colman
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

Review 3.  Aspects of C1-inhibitor biochemistry and pathophysiology.

Authors:  T K Nilsson
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

4.  Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria.

Authors:  K Bork; G Witzke; K Artmann; P Benes; M Böckers; W Kreuz
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

Review 5.  Overview: pharmacology of ticlopidine.

Authors:  J L Gordon
Journal:  Agents Actions Suppl       Date:  1984

6.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

7.  Recombinant alpha 1-antitrypsin Pittsburgh (Met 358----Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment.

Authors:  M Schapira; M A Ramus; S Jallat; D Carvallo; M Courtney
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

8.  Platelet C1- inhibitor. A secreted alpha-granule protein.

Authors:  A H Schmaier; P M Smith; R W Colman
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.